7th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards 2014
Pharmaleaders is back again like every year with a bang & this time with a yet another message. The Message is very loud & clear. Healthcare has no substitutes & Pharmaleaders means business. With the new Modi Government at the Centre, Pharmaleaders is hopeful of a plethora of reforms to see our country smiling both by companies & patients. Pharmaleaders voce the opinion of Less Regulation, Less Bureaucracy & more & more easing of business transactions. Unlike last year, this Summit is debating on two important Sessions. in a uniquely positioned full day program encompassing two themes “Make In India – Healthcare Reforms , Insurance,Innovations,Investments & Infrastructure” & Empowering India’s Developing Healthcare System - Investing the Healthcare Solutions of Tomorrow in difficult Times at the Sahara Star, Mumbai International Airport in Mumbai, India, on December,26th , 2014. This historic Summit is supported by the Government of India at the Centre & is actively supported by the Ministry of Health & Family Affairs, Govt of India, Ministry of Commerce Pharmaceuticals , Government of india & host of other trade bodies. The real focus is Make In India Campaign & I sincerely believe that our manufacturing sector will flourish tremendously in next couple of years as we hopefully will see plethora of reforms & industry friendly regulations. I have reason to believe it happen as India is expected to rank amongst the top three pharmaceutical markets in terms of incremental growth by 2020 as India’s generic drugs account for 20% of global exports in terms of volume, making the country the largest provider of generic medicines globally. While the Industry revenues are expected to expand at a CAGR of 12.1% during 2012-20 and reach USD 45 Billion, the healthcare sector in India is expected to grow to USD 250 Billion by 2020 from USD 65 Billion currently & the generics market is expected to grow to USD 26.1 Billion by 2016 from USD 11.3 Billion in 2011. 100%. Currently FDI is allowed under the automatic route for Greenfield Projects & for brownfield project investments, up to 100% FDI is permitted under the government route & the government is likely to incorporate appropriate conditions for FDI in brownfield cases, at the time of granting approvals. India will attract foreign players as is evident from the fact that India is expected to be the third largest global market for active pharmaceutical ingredients by 2016, with a 7.2% increase in market share with indian pharma companies registering 49% of overall Drug Master Filings (DMF) filed in the US in 2012 . The Contract Research and Manufacturing Services industry (CRAMS) – estimated at USD 8 Billion in 2015, up from USD 3.8 Billion in 2012. The market has more than1000 players. The formulations industry – India is the largest exporter of formulations with 14% market share and ranks 12th in the world in terms of export value. Double-digit growth is expected over the next five yea
